114 related articles for article (PubMed ID: 12583818)
1. A systematic review update of the clinical effectiveness and cost-effectiveness of glycoprotein IIb/IIIa antagonists.
Robinson M; Ginnelly L; Sculpher M; Jones L; Riemsma ; Palmer S; Philips Z; Glanville J
Health Technol Assess; 2002; 6(25):1-160. PubMed ID: 12583818
[No Abstract] [Full Text] [Related]
2. Risks and benefits of glycoprotein IIb/IIIa antagonists in acute coronary syndrome.
Latour-Pérez J
Ann Pharmacother; 2001 Apr; 35(4):472-9. PubMed ID: 11302412
[TBL] [Abstract][Full Text] [Related]
3. [Safety and economic efficiency of platelet IIb/IIIa receptor blockers in acute coronary syndromes without ST-segment elevation].
Latour-Pérez J
Rev Esp Cardiol; 2000 Aug; 53(8):1148-50. PubMed ID: 11032540
[No Abstract] [Full Text] [Related]
4. Newer therapeutic concept in antiplatelet aggregation inhibition--GPIIb-IIIa receptor antagonists.
Malhotra S; Mishra NK; Sinha RS; Gupta B
J Assoc Physicians India; 2000 Mar; 48(3):329-34. PubMed ID: 11229122
[TBL] [Abstract][Full Text] [Related]
5. Glycoprotein IIb/IIIa inhibitors.
Herbert ME; Brewster GS
Ann Emerg Med; 1999 Sep; 34(3):407-10. PubMed ID: 10459103
[No Abstract] [Full Text] [Related]
6. Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?
Palmer S; Sculpher M; Philips Z; Robinson M; Ginnelly L; Bakhai A; Abrams K; Cooper N; Packham C; Alfakih K; Hall A; Gray D
Int J Cardiol; 2005 Apr; 100(2):229-40. PubMed ID: 15823630
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy of platelet IIb/IIIa receptor blockers in acute coronary syndromes].
Sitges M; Bosch X; Sanz G
Rev Esp Cardiol; 2000 Mar; 53(3):422-39. PubMed ID: 10712972
[TBL] [Abstract][Full Text] [Related]
8. The evolving role of glycoprotein IIb/IIIa inhibitor therapy in contemporary care of acute coronary syndrome patients.
Tricoci P; Peterson ED
J Interv Cardiol; 2006 Oct; 19(5):449-55. PubMed ID: 17020570
[TBL] [Abstract][Full Text] [Related]
9. More drugs pass the NICE test.
MacDonald R
BMJ; 2000 Oct; 321(7265):853. PubMed ID: 11021859
[No Abstract] [Full Text] [Related]
10. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications.
van Hout BA; Bowman L; Zelinger DJ; Simoons ML
Eur Heart J; 1998 Apr; 19 Suppl D():D59-66. PubMed ID: 9597523
[TBL] [Abstract][Full Text] [Related]
11. Glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Maree A; Fitzgerald D
Haematologica; 2001 Nov; 86(11 Suppl 2):45-8. PubMed ID: 11926777
[No Abstract] [Full Text] [Related]
12. Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications.
Hillegass WB; Newman AR; Raco DL
Pharmacoeconomics; 2001 Jan; 19(1):41-55. PubMed ID: 11252545
[TBL] [Abstract][Full Text] [Related]
13. [Glycoprotein IIb/IIIa receptor antagonists for improving thrombolytic and interventional therapy in patients with acute myocardial infarct].
Zeymer U; Neuhaus KL
Dtsch Med Wochenschr; 2000 Oct; 125(43):1297-300. PubMed ID: 11098229
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
Summers KM; Holdford DA; Crouch MA
Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
[TBL] [Abstract][Full Text] [Related]
15. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
Adgey AA
Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518
[TBL] [Abstract][Full Text] [Related]
16. IIb/IIIa platelet inhibitors in the management of coronary artery disease.
Talley JD
J Ark Med Soc; 1996 Oct; 93(5):237-9. PubMed ID: 8908943
[No Abstract] [Full Text] [Related]
17. Glycoprotein IIb/IIIa platelet receptor blockers: are they ready for prime time in patients with unstable coronary artery disease?
Conti CR
Clin Cardiol; 1999 Feb; 22(2):57-8. PubMed ID: 10068840
[No Abstract] [Full Text] [Related]
18. [Use of platelet glycoprotein IIb/IIIa receptor inhibitors in acute coronary syndrome and coronary intervention].
Kakuta T; Kishi Y; Numano F
Nihon Rinsho; 1998 Oct; 56(10):2630-4. PubMed ID: 9796330
[TBL] [Abstract][Full Text] [Related]
19. Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
Vorchheimer DA; Fuster V
Circulation; 1998 Feb; 97(4):312-4. PubMed ID: 9468202
[No Abstract] [Full Text] [Related]
20. [Glycoprotein IIB/IIIA receptor blockers as treatment of acute coronary syndromes and interventional cardiology].
Abramovitch N; Halon DA; Flugelman Y; Lewis BS
Harefuah; 1998 Jul; 135(1-2):41-7. PubMed ID: 10909532
[No Abstract] [Full Text] [Related]
[Next] [New Search]
